Drug Database
IM

immune globulin intravenous (Iveegam, Immuno / Iveegam EN)

✓ Approved

Baxter International, Inc. · Polyclonal Antibodies · Polyclonal Antibodies

What is immune globulin intravenous?

immune globulin intravenous is a polyclonal antibodies developed by Baxter International, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesIveegam, Immuno, Iveegam EN
CompanyBaxter International, Inc.
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Baxter International, Inc.

Therapeutic Indications

immune globulin intravenous is developed for 5 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Immune system disordersSelective IgG subclass deficiency✓ Approved
Infections and infestationsBorna virus infection✓ Approved
Musculoskeletal and connective tissue disordersDermatomyositisPreclinical
Musculoskeletal and connective tissue disordersPolymyositisPreclinical
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritisPreclinical

Related Research Articles

PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Aplastic anemia developed after treatment with durvalumab].

Maeshima Kaho K, Sakayori Yo Y, Yokoyama Hiroki H, Katsube Atsushi A et al.

A 76-year-old woman with stage IIIB squamous cell lung carcinoma developed pancytopenia following maintenance therapy with durvalumab. She was diagnosed with squamous cell lung carcinoma (T4N2M0, stageIIIB) in December 2023. Following a favorable response to chemoradiotherapy, maintenance therapy with durvalumab was initiated in June 2024. Thrombocytopenia was observed starting in August, and platelet count had decreased to 22,000/µl in October, leading to the discontinuation of durvalumab. However, the condition progressed to pancytopenia. Bone marrow biopsy revealed hypocellular marrow without dysplasia, fibrosis, or hemophagocytosis. Additional findings included paroxysmal nocturnal hemoglobinuria-type blood cells and fatty marrow replacement on spinal MRI. Based on these comprehensive findings, the patient was diagnosed with aplastic anemia (AA) in January 2025. Immunosuppressive therapy combining antithymocyte globulin, cyclosporine A, and eltrombopag was initiated in February 2025, resulting in a favorable response. AA is a relatively rare immune-related adverse event, and reports of AA induced by durvalumab are extremely limited. This case highlights the importance of considering AA in the differential diagnosis of persistent thrombocytopenia or pancytopenia during immune checkpoint inhibitor therapy.

PMID 42669502
Read full article →
PubMedCureus2026-08-30

Sequential Immune-Mediated Extrahepatic Complications of Hepatitis E Virus: A Case Report.

Padarabinda Tripathy Krishna K, Mishra Subhashree S, Laxman Virani A VA, Hima Varsha Palle Sree PS et al.

Hepatitis E virus (HEV) infection is classically described as causing self-limiting acute hepatitis. However, it is increasingly being recognised for a wide spectrum of immune-mediated extrahepatic complications involving the haematological, neurological, renal and pancreatic systems. These manifestations are more commonly seen as isolated presentations in individual patients. We report a 59-year-old man with serologically confirmed acute hepatitis E, in whom alternative infectious, autoimmune, and malignant etiologies were excluded, who developed three distinct immune-mediated complications in temporal sequence during a single hospital admission: autoimmune haemolytic anaemia (AIHA) at presentation, secondary haemophagocytic lymphohistiocytosis (HLH) within one week, and Guillain-Barré syndrome (GBS) on day 17. The chronological evolution of these complications suggested a progressive triphasic immune-mediated response following acute HEV infection. Each complication was diagnosed using established criteria and managed with targeted therapy-corticosteroids and supportive care for AIHA; etoposide, escalated dexamethasone, and cyclosporin for HLH; and intravenous immunoglobulin for GBS. The sequential development from early autoantibody-mediated haemolysis to hyperinflammatory macrophage activation and subsequent delayed post-infectious neuroimmune involvement reflects evolving immune dysregulation rather than coincident multisystem disease. The patient achieved complete clinical and biochemical recovery on follow-up. Sequential occurrence of AIHA, HLH, and GBS following acute HEV infection within a single hospital admission is rarely described. The case underscores the importance of maintaining a high index of suspicion for evolving extrahepatic immune-mediated complications in patients with acute HEV infection.

PMID 42668655
Read full article →
PubMedAdvances in colloid and interface science2026-08-30

From wetting mechanisms to anti-wetting membrane design: An interfacial and colloidal perspective on membrane distillation.

Omer Abduelrahman Adam AA, Wang Duo D, Wang Yong Y, Yang Chao C

Membrane distillation (MD) is a promising thermally driven desalination technology due to its high rejection of non-volatile contaminants and its ability to operate under relatively mild conditions. However, membrane wetting remains a persistent challenge that hinders its distillation efficiency and long-term application. This review presents a mechanism-based perspective on MD wetting by linking capillary pressure imbalance, surface-tension reduction, surfactant adsorption, scaling, and colloid-driven interfacial interactions to pore invasion and performance deterioration. The influence of key membrane properties, including hydrophobicity, liquid entry pressure, surface free energy, pore structure, and thermal conductivity, was discussed in relation to wetting resistance. Building on this mechanistic understanding, four anti-wetting strategies are examined, including stabilization of the Cassie-Baxter state through hierarchical structures, extension of liquid repellency using ultralow-surface-energy materials, asymmetric interfacial regulation through Janus architectures, and dynamic interfacial regulation using stimuli-responsive membranes. Furthermore, the role of engineered colloidal nanomaterials as versatile building blocks for anti-wetting interfaces is discussed across the four design strategies. Artificial intelligence and machine learning, particularly inverse design and physics-informed approaches, are highlighted as emerging tools for membrane discovery and optimization. Future perspectives are outlined toward mechanism-guided membrane fabrication, validation under realistic feed conditions, and data-driven design of durable anti-wetting MD membranes. This review proposes anti-wetting strategies as well as design principles in the separation applications.

PMID 42669237
Read full article →
PubMedThe Journal of veterinary medical science2026-08-30

Incidence of emesis induced by low-dose intravenous medetomidine administration in dogs: a retrospective study of 155 cases.

Kanda Teppei T, Ohashi Yusuke Y, Ohta Mai M, Saeki Kanna K et al.

This study aimed to determine the incidence of emesis in dogs receiving a low dose of intravenous medetomidine. Anesthetic records of dogs that received ≤3 µg/kg medetomidine intravenously before anesthesia induction were retrospectively reviewed. Data included demographics, doses, and the presence of emesis, retching, sialorrhea, or lip licking. A total of 155 cases met the criteria. The administered dose of medetomidine was 3.0 (0.5-3.0) µg/kg (median [range]). Emesis occurred in 3 of 155 dogs (1.9%), while retching, sialorrhea, and lip licking occurred in two, two, and five dogs, respectively. The incidence of emesis observed in dogs receiving low-dose (≤3 µg/kg) intravenous medetomidine was lower than that reported in studies using higher doses.

PMID 42669473
Read full article →
PubMedParasite epidemiology and control2026-08-30

Co-infection with Schistosoma mansoni and Helicobacter pylori: epidemiological patterns and implications for integrated control.

Ahmed Ashraf Fawzy Mosa AFM, Ali Hala Shehata HS, Alhussainy Nabeel H NH, El-Wahsh Hany M HM et al.

Co-infections with Schistosoma mansoni and Helicobacter pylori are frequently reported in low-resource endemic settings; however, their combined systemic and hematological effects in true co-endemic populations remain incompletely characterized. While S. mansoni transmission is primarily driven by exposure to agricultural water, H. pylori reflects persistent household and sanitation-related transmission, highlighting distinct yet overlapping epidemiological pathways. This study aimed to assess the association between occupational freshwater exposure and S. mansoni infection and to evaluate the clinical, hematological, and biochemical profiles associated with S. mansoni and H. pylori mono- and co-infections in a rural Egyptian population. A community-based, cross-sectional study was conducted in a rural agricultural village in Egypt. Participants were stratified into four groups: S. mansoni mono-infection (Gp1), S. mansoni-H. pylori co-infection (Gp2), H. pylori mono-infection (Gp3), and uninfected controls (Gp4). Clinical assessment, stool microscopy using the Kato-Katz thick smear technique, H. pylori coproantigen ELISA, complete blood counts, and serum biochemical analyses were performed. Comparative statistical analyses were used to evaluate group differences and associated risk factors. Occupational exposure (farm work) was strongly associated with S. mansoni infection (P < 0.001), reinforcing its role as a key transmission driver in rural endemic settings. Gastrointestinal symptoms were largely non-specific, although hematochezia occurred exclusively among individuals infected with S. mansoni. Co-infection did not significantly influence H. pylori antigen levels (P = 0.190), indicating limited biological interaction between the pathogens. Systemic alterations were predominantly driven by S. mansoni, including thrombocytopenia and marked eosinophilia (P < 0.001), alongside elevated serum globulin levels (P = 0.037), suggesting sustained immune activation. Other biochemical parameters showed no significant differences. In endemic rural settings, co-infection with S. mansoni and H. pylori does not demonstrate synergistic systemic effects but rather reflects overlapping transmission pathways with distinct epidemiological determinants. These findings suggest that integrated screening strategies may offer limited additional clinical benefit beyond pathogen-specific management, while still supporting coordinated control efforts targeting shared risk environments.

PMID 42668635
Read full article →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm].

Abe Shintaro S, Izumi Shintaro S, Tsukamoto Shokichi S, Miyamoto Izumi I et al.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for blast-phase myeloproliferative neoplasms (BP-MPN), although relapse rates remain high. Recently, conditioning with thiotepa, busulfan, and fludarabine (TBF) has shown promising anti-leukemic activity in acute myeloid leukemia. A 64-year-old man with essential thrombocythemia that progressed to secondary myelofibrosis and subsequently BP-MPN underwent allo-HSCT after cytoreduction with azacitidine plus venetoclax. Peripheral blood stem cells were obtained from an HLA allele-matched unrelated donor, and TBF was used as the conditioning regimen. Low-dose anti-thymocyte globulin was administered for graft-versus-host disease (GVHD) prophylaxis. Full donor chimerism was achieved on day 28 after transplantation. Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) improved with defibrotide, and acute GVHD was manageable. This case suggests that a multidisciplinary treatment strategy incorporating TBF conditioning may improve relapse-free survival in patients with BP-MPN.

PMID 42669508
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about immune globulin intravenous